All In Biotech

Drug Trial Radar · NCT01677572

Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease

A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease

Last checked: Nov 20, 2026Latest source record: Aug 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 197 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

197

Actual

Start

Oct 5, 2012

Primary completion

Jul 31, 2019

Study completion Jul 31, 2019

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Sep 3, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 50 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the safety and tolerability of multiple doses of Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb) in participants with prodromal or mild Alzheimer's Disease (AD). The secondary objectives of this study are to assess the effect on cerebral amyloid plaque content as measured by florbetapir-fluorine-18 (18F-AV-45F-AV-45) positron emission tomography (PET) imaging, to assess the multiple dose serum concentrations of Aducanumab and to evaluate the immunogenicity of Aducanumab after multiple dose administration in this population.

Conditions

  • Alzheimer's Disease

Interventions

  • Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb)Drug

    Participants will receive an infusion of Aducanumab on Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, and 365 (±2 days) at the study clinic and assigned does levels. The infusion will be administered for approximately 1 hour. The study is conducted with a staggered, parallel group design, with the first 3 treatment arms conducted in parallel, 2 further treatment arms subsequently beginning in parallel and the 2 last treatment arms subsequently beginning in parallel. Qualifying participants can enter the long-term extension period at doses described in the treatment arms for up to an additional 112 doses.

  • PlaceboDrug

    Placebo to mimic the low dose, mid-dose and high-dose treatment arms of the experimental intervention; administered by intravenous (IV) infusion on Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, and 365 (±2 days) at the study clinic. Qualifying participants can enter the long-term extension period at doses described in the treatment arms for up to an additional 112 doses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse EventsTime frame: Baseline to week 518

Locations

32 sites in 1 country. Site status is shown where the registry gives one.

  • NNS Clinical Research, LLC

    Tucson, Arizona

  • Senior Clinical Trials, Inc.

    Laguna Hills, California

  • Torrance Clinical Research Institute, Inc.

    Lomita, California

  • Collaborative Neuroscience Network, LLC

    Long Beach, California

  • University of California, Los Angeles

    Los Angeles, California

  • Pacific Neuroscience Medical Group

    Oxnard, California

  • Pacific Research Network, Inc.

    San Diego, California

  • San Francisco Clinical Research Center

    San Francisco, California

  • Stanford University Medical Center

    Stanford, California

  • Alzheimer's Disease Research Unit, Yale University

    New Haven, Connecticut

  • Georgetown University Hospital

    Washington D.C., District of Columbia

  • Brain Matters Research, Inc.

    Delray Beach, Florida

  • Neuropsychiatric Research Center of Southwest Florida

    Fort Myers, Florida

  • MD Clinical Trials, Inc.

    Hallandale, Florida

  • Miami Jewish Health Systems

    Miami, Florida

  • Galiz Research, LLC

    Miami Springs, Florida

  • Compass Research, LLC

    Orlando, Florida

  • Infinity Clinical Research, Inc.

    Sunrise, Florida

  • Axiom Clinical Research of Florida

    Tampa, Florida

  • Stedman Clinical Trials, LLC

    Tampa, Florida

  • Neurostudies.net, LLC

    Decatur, Georgia

  • Alexian Brothers Neurosciences Institute

    Elk Grove Village, Illinois

  • Indiana University School of Medicine

    Indianapolis, Indiana

  • St. Louis Clinical Trials, LLC

    St Louis, Missouri

  • Memory Enhancement Center of America, Inc.

    Eatontown, New Jersey

  • CRI Lifetree

    Marlton, New Jersey

  • Advanced Memory Research Institute of NJ

    Toms River, New Jersey

  • Empire Neurology, PC

    Latham, New York

  • Insight Clinical Trials LLC

    Beachwood, Ohio

  • Summit Research Network (Oregon) Inc.

    Portland, Oregon

  • Brown Hospital

    East Providence, Rhode Island

  • Rhode Island Hospital

    Providence, Rhode Island

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.